CN Patent

CN102250065B — 取代的三嗪苯脲衍生物及其用途

Assigned to Zhejiang Hisun Pharmaceutical Co Ltd · Expires 2015-05-13 · 11y expired

What this patent protects

本发明涉及取代的三嗪苯脲衍生物及其作为蛋白激酶特别是Raf-1的抑制剂的应用，本发明化合物可用于治疗各种紊乱和疾病，特别是与蛋白激酶相关的疾病，如癌症、心肌梗塞、脑血栓、贫血和丙型肝炎(HCV)等。

USPTO Abstract

本发明涉及取代的三嗪苯脲衍生物及其作为蛋白激酶特别是Raf-1的抑制剂的应用，本发明化合物可用于治疗各种紊乱和疾病，特别是与蛋白激酶相关的疾病，如癌症、心肌梗塞、脑血栓、贫血和丙型肝炎(HCV)等。

Drugs covered by this patent

infigratinib-phosphate (INFIGRATINIB PHOSPHATE)

Patent Metadata

Patent number: CN102250065B
Jurisdiction: CN
Classification: —
Expires: 2015-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Zhejiang Hisun Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.